10-Q quarterly report · filed Nov 10, 2026

Scholar Rock Holding Corp (SRRK) Q3 2026 10-Q Quarterly Report

Short answer

Scholar Rock Holding Corp (SRRK) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $570,000 with net income of −$107M.

Q3 2026 key financials · XBRL

Revenue
$570,000
Net income
−$107M
−4.9% YoY · +2.4% QoQ
Operating margin
-18607.2%
EPS (diluted)
−$0.81
+9.0% YoY · +3.6% QoQ

Source: XBRL data from the Scholar Rock Holding Corp (SRRK) Q3 2026 10-Q on SEC EDGAR. USD.

Scholar Rock Holding Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $0.6M from ISEMBYLD, versus $0 in Q3 2025
  • Gross margin approximately 98.7%, based on $0.6M revenue and $8,000 cost of revenue
  • Best-performing program SRK-439 R&D costs $2.9M, up 77.4% YoY; apitegromab costs $20.0M, down 6.5%
  • Cash, equivalents and marketable securities $413.6M, up $46.0M from December 31, 2025
  • Operating cash use $234.2M; financing provided $280.0M, including $160.8M ATM proceeds and $197.7M debt proceeds

Risk Factors

  • Newly added commercialization risk: FDA approved ISEMBYLD on September 11, 2026, making U.S. launch execution critical to revenue and profitability
  • Most material regulatory update: third-party fill-finish facility received OAI classifications in 2025 and 2026, delaying EU approval and forcing MAA resubmission
  • Regulatory pricing risk: CMS finalized GLOBE on October 2, 2026, requiring incremental Medicare Part B rebates beginning January 1, 2027
  • Near-term operational risk: single-source apitegromab drug substance and fill-finish suppliers expose commercial supply to disruptions and batch failures
  • Financial risk: ongoing net losses and additional capital requirements remain necessary to fund ISEMBYLD commercialization and pipeline development

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Scholar Rock Holding Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.